OpenNeedle Ask your own

Question explored with the scientific record

Conversation so far

  1. 1 Recommend treatment for memory loss
  2. 2 HRT side effects
  3. 3 HRT side effects

Answered on this page ↓

HRT side effects

Oct 27, 2026 · 3 sources used · OpenNeedle synthesis
HRT's most consistent side effect is a small, real rise in breast cancer risk, and it depends almost entirely on whether you take estrogen alone or with a progestin.

The two are not the same drug. Estrogen plus progestin raises breast cancer incidence and deaths from it [1][2]. Estrogen alone, in women who have had a hysterectomy, was associated with lower breast cancer incidence and mortality in the same trial [1]. That split is the single most important thing to know before deciding.

The combined regimen's numbers are modest but not zero. In a Norwegian cohort of 160,881 women, current estrogen-progestin users had about a 44% higher rate of breast cancer than never-users, and risk climbed roughly 4% per year of use [2]. Breast cancer deaths were also higher [2]. A 2002 review noted the same pattern but concluded the added risk was "not proved" [3]; the later randomized and cohort data settled that question against it [1][2].

RegimenBreast cancer incidenceBreast cancer death
Estrogen + progestinhigher [1][2]higher [1][2]
Estrogen alonelower [1]lower [1]

The endometrial cancer tradeoff runs the other way: unopposed estrogen raises it, and adding a progestin offsets that [1]. So the progestin that protects the uterus is the piece that raises the breast signal. That is the real tradeoff, and it is not a small one.

My call: if you have a uterus and need a progestin, the breast risk is real and rises with years of use, so the shortest effective course is the honest default. If you have had a hysterectomy, estrogen alone looks materially safer on the breast. Confidence: moderate on the direction of both signals, low on how much dose, route, and formulation shift the numbers, because the records here do not settle that.

Keep digging

Sources used 3

  1. Menopausal hormone therapy and breast cancer mortality: clinical implications Therapeutic Advances in Drug Safety (2015) Thin

    Combination menopausal hormone therapy with estrogen plus progestin increases breast cancer incidence and mortality and impairs detection, while estrogen alone reduces breast cancer incidence and mortality in women with prior hysterectomy, informing nuanced clinical use.

    DOI: 10.1177/2042098614568300
  2. Menopausal hormone therapy and incidence, mortality, and survival of breast cancer subtypes: a prospective cohort study Breast Cancer Research (2024) primary study Strong

    Current estrogen-progestin therapy was associated with increased incidence and mortality of overall and luminal A-like breast cancer, but not worse overall survival after diagnosis; pre-diagnostic use was associated with better triple-negative survival.

    DOI: 10.1186/s13058-024-01897-4
  3. Risk of breast cancer with estrogen‐progestin replacement therapy International Journal of Gynecology & Obstetrics (2002) commentary Strong

    This ACOG Committee Opinion critically evaluates evidence suggesting that adding progestins to estrogen HRT may increase breast cancer risk, but concludes the increased risk has not been proved.

    DOI: 10.1016/s0020-7292(02)90019-6

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question →